CorMedix [CRMD] vs Regeneron [REGN] Detailed Stock Comparison

CorMedix Inc.

NASDAQ
Loading...

Regeneron Pharmaceuticals, Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: CorMedix Inc. wins in 11 metrics, Regeneron Pharmaceuticals, Inc. wins in 9 metrics, with 0 ties. CorMedix Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric CorMedix Inc. Regeneron Pharmaceuticals, Inc. Better
P/E Ratio (TTM) 3.64 18.00 CorMedix Inc.
Price-to-Book Ratio 1.45 2.45 CorMedix Inc.
Debt-to-Equity Ratio 36.74 9.51 Regeneron Pharmaceuticals, Inc.
PEG Ratio -0.20 -4.80 CorMedix Inc.
EV/EBITDA 3.36 16.72 CorMedix Inc.
Profit Margin (TTM) 52.31% 31.41% CorMedix Inc.
Operating Margin (TTM) 53.90% 23.13% CorMedix Inc.
EBITDA Margin (TTM) 53.90% 23.13% CorMedix Inc.
Return on Equity 66.56% 14.86% CorMedix Inc.
Return on Assets (TTM) 21.21% 5.91% CorMedix Inc.
Free Cash Flow (TTM) $172.79M $3.77B Regeneron Pharmaceuticals, Inc.
Dividend Yield N/A 0.59% N/A
1-Year Return -30.48% 25.39% Regeneron Pharmaceuticals, Inc.
Price-to-Sales Ratio (TTM) 1.88 5.50 CorMedix Inc.
Enterprise Value $586.94M $70.98B Regeneron Pharmaceuticals, Inc.
EV/Revenue Ratio 1.88 4.95 CorMedix Inc.
Gross Profit Margin (TTM) 83.43% 84.95% Regeneron Pharmaceuticals, Inc.
Revenue per Share (TTM) $4 $137 Regeneron Pharmaceuticals, Inc.
Earnings per Share (Diluted) $2.04 $41.48 Regeneron Pharmaceuticals, Inc.
Beta (Stock Volatility) 1.41 0.40 Regeneron Pharmaceuticals, Inc.
Short % of Float 20.08% 2.55% Regeneron Pharmaceuticals, Inc.

CorMedix Inc. vs Regeneron Pharmaceuticals, Inc. Stock Performance Analysis

Loading Price Chart...

CRMD
REGN

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
CorMedix Inc.-2.11%-0.95%8.15%32.70%-20.83%-31.25%
Regeneron Pharmaceuticals, Inc.1.07%3.36%-9.51%-16.93%-11.54%-18.14%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
CorMedix Inc.-30.48%64.20%13.29%-37.94%6.84%-31.38%
Regeneron Pharmaceuticals, Inc.25.39%-16.92%20.10%53.41%959.24%4,557.42%

Performance & Financial Health Analysis: CorMedix Inc. vs Regeneron Pharmaceuticals, Inc.

MetricCRMDREGN
Market Information
Market Cap i$586.55M$80.98B
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i941,900642,495
90 Day Avg. Volume i1,136,190617,765
Last Close$8.36$635.45
52 Week Range$6.13 - $17.43$476.49 - $821.11
% from 52W High-52.04%-22.61%
All-Time High$52.00 (Mar 30, 2015)$1,211.20 (Aug 26, 2024)
% from All-Time High-83.92%-47.54%
Growth Metrics
Quarterly Revenue Growth3.12%0.03%
Quarterly Earnings Growth0.04%-0.08%
Financial Health
Profit Margin (TTM) i0.52%0.31%
Operating Margin (TTM) i0.54%0.23%
Return on Equity (TTM) i0.67%0.15%
Debt to Equity (MRQ) i36.749.51
Cash & Liquidity
Book Value per Share (MRQ)$5.11$304.65
Cash per Share (MRQ)$1.88$83.86
Operating Cash Flow (TTM) i$175.05M$4.98B
Levered Free Cash Flow (TTM) i$108.51M$3.26B
Dividends
Last 12-Month Dividend Yield iN/A0.59%
Last 12-Month Dividend iN/A$4.46

Valuation & Enterprise Metrics Analysis: CorMedix Inc. vs Regeneron Pharmaceuticals, Inc.

MetricCRMD (Apr 26, 2026)REGN (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i3.6418.00
Forward P/E i10.3114.21
PEG Ratio i-0.20-4.80
Price to Sales (TTM) i1.885.50
Price to Book (MRQ) i1.452.45
Market Capitalization
Market Capitalization i$586.55M$80.98B
Enterprise Value i$586.94M$70.98B
Enterprise Value Metrics
Enterprise to Revenue i1.884.95
Enterprise to EBITDA i3.3616.72
Risk & Other Metrics
Beta i1.410.40
Book Value per Share (MRQ) i$5.11$304.65

Financial Statements Comparison: CorMedix Inc. vs Regeneron Pharmaceuticals, Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricCRMD (2025)REGN (2025)
Revenue/Sales i311.71M14.34B
Cost of Goods Sold i35.96M2.10B
COGS % of Revenue i11.5%14.6%
Gross Profit i275.75M12.24B
Gross Margin i88.5%85.4%
Research & Development i19.33M5.85B
Operating Income (EBIT) i150.14M3.70B
Operating Margin i48.2%25.8%
EBITDA i168.54M5.00B
EBITDA Margin i54.1%34.8%
Pre-Tax Income i150.02M5.23B
Pre-Tax Income % of Revenue i48.1%36.5%
Income Tax i-13.04M725.80M
Income Tax % of Revenue i-4.2%5.1%
Net Income (Profit) i163.06M4.50B
Profit Margin i52.3%31.4%

Balance Sheet & Liquidity Metrics

MetricCRMD (2025)REGN (2025)
Cash & Equivalents i144.84M3.12B
Total Current Assets i367.05M18.02B
Total Current Assets % of Revenue i117.8%125.7%
Total Current Liabilities i174.27M4.37B
Total Current Liabilities % of Revenue i55.9%30.5%
Long-Term Debt i147.47M2.71B
Long-Term Debt % of Revenue i47.3%18.9%
Total Shareholders Equity i405.31M31.26B
Retained Earnings i-176.58M35.80B
Retained Earnings % of Revenue i-56.6%249.6%
Property, Plant & Equipment i8.98M1.54B

Cash Flow Statement Comparison

MetricCRMD (2025)REGN (2025)
Operating Cash Flow i81.53M6.30B
Operating Cash Flow % of Revenue i26.2%43.9%
Capital Expenditures i-2.26M0
Free Cash Flow i172.79M3.77B
FCF Margin i55.4%26.3%
Debt Repayment iN/AN/A
Common Stock Repurchase iN/A-3.97B

Short Interest & Institutional Ownership Analysis

MetricCRMDREGN
Shares Short i15.72M2.55M
Short Ratio i13.344.46
Short % of Float i20.08%2.55%
Shares Outstanding i79.26M105.72M
Float Shares i68.04M98.55M
% Held by Insiders i7.98%1.98%
% Held by Institutions i55.13%91.08%
% Held by Public i36.89%6.94%

Dividend Analysis & Yield Comparison: CorMedix Inc. vs Regeneron Pharmaceuticals, Inc.

MetricCRMDREGN
Last 12-Month Dividend iN/A$4.46
Last 12-Month Dividend Yield iN/A0.59%
3-Year Avg Annual Dividend iN/A$1.49
3-Year Avg Dividend Yield iN/A0.13%
3-Year Total Dividends iN/A$4.46
Ex-Dividend DateN/AFeb 20, 2026